(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Freed whale gets stranded again off German coast- Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- 21 Incredibly Interesting Contemplations To Observe Consistently
- Norovirus infections increase significantly, with positive test rates reaching 14%
- Two Israeli infants among wounded by shrapnel in overnight Iranian missile barrage
- Astronaut on ISS captures spectacular orbital video of zodiacal light, auroras and the Pleiades
- Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out
- She was the ultimate '90s fitness influencer. Now she's delivering Uber Eats — and rebuilding her life.
- January’s full wolf supermoon and the Quadrantid meteor shower will start off the new year
